Core Technology Platforms Utilizing CAR T-Cells

Harnessing advanced cell and gene engineering strategies, including chimeric antigen receptor (CAR) and genome editing, SenlangBio has developed unique core technology platforms to generate cancer-fighting immune effector cell therapies.


Our Competitive Advantages

  • Total solutions in the cell-tech industry sector with seamless integration of innovative research, process development, standardization, validation, quality assessment/ quality control, bio-manufacturing, and clinical development, therefore, greatly accelerating the translation of technology to clinical application, as well as lowering overall manufacturing costs.
  • Diverse and broad repertoire of pipeline candidates covering solid tumor and hematologic malignancies, including both autologous and universal ("off-the-shelf") cell therapy candidates.
  • Advanced cell/gene engineering and proprietary cell expansion expertise that enable the design and development of cell therapy candidates with superior therapeutic efficacy and safety profiles.
  • Our differentiating competence is our capability to achieve seamless integration of our innovative research, broad repertoire of pipeline candidates, state-of-the-art bio-manufacturing/bio-processing infrastructure, as well as rapid implementation of clinical programs.

CAR T-Cell Therapy Platform

Our CAR T-cell therapy platform gives us the ability to design CAR T-cells to recognize a unique antigen on targeted tumor cells and specifically recognize and kill those cancerous cells that have the targeted antigen on their surface.

View Our CAR-T Platform

CAR-γδT Therapy Platform

Our allogeneic (universal) CAR-γδT technology develops donor-derived γδT cells that provide superior anti-tumor effectiveness.

View Our CAR-GDT Platform

Tumor-infiltrating Lymphocytes (TILs) Cell Therapy Platform

Our armored tumor-infiltrating lymphocytes (armTILs) technology delivers cancer-killing T-cells that provide a unique “personalized” cellular immunotherapy approach.

View Our TILs Platform